Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q4 EPS of $0.07, $0.16 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $108.45 million versus the consensus estimate of $106.96 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.